Abstract
The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
European Organization for Research on the Treatment of Cancer, Cooperative Group for Leukemias and Hematosarcomas: Clinical Screening of Epipodophyllotoxin VM 26 in malignant lymphomas and solid tumors. Br Med J 2:744–748, 1972
Spremulli E: Phase II study of VM 26 in adult malignancies. Cancer Treat Rep 64: 147–149, 1980
O'Dwyer P, Alonso MT, Leyland-Jones B, Marsoni S: Teniposide: A review of 12 years of experience. Cancer Treat Rep 68:1455–1466, 1984
DeSimone P, Gams R, Bartolucci A: Phase II studies of mitoxantrone (dihydroxyanthracinadione) in the treatment of advanced colorectal carcinoma. Am J Clin Oncol 7:517–522, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cox, E.B., Vogel, C.L., Carpenter, J.T. et al. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. Invest New Drugs 6, 37–40 (1988). https://doi.org/10.1007/BF00170777
Issue Date:
DOI: https://doi.org/10.1007/BF00170777